

SUPPLEMENTARY TABLES

Table S3. Other exploratory outcome analysis results.

	Ratio vs baseline		Ratio (95% CI), AZD8601 vs placebo
	AZD8601 3 mg (<i>n</i> = 7)	Placebo (<i>n</i> = 4)	
Cardiac biomarkers at 6 months			
High-sensitivity troponin T, µg/L	1.008	1.167	0.86 (0.44, 1.71); <i>P</i> = 0.670
VEGF-A at 1 month			
VEGF-A plasma concentration, pg/mL	1.121	1.087	1.03 (0.45, 2.37); <i>P</i> = 0.935
VEGF-A area under the plasma concentration–time curve (0–72 h), pg × h/mL	4164.481	3830.110	1.09 (0.88, 1.34); <i>P</i> = 0.372

Cardiac biomarker data are from a mixed model repeated measures with treatment, visit, and visit-by-treatment interaction as fixed factors, subject as random factor and baseline value as covariate. Two-sided nominal *P*-values are presented.

VEGF-A data are from an analysis of covariance model with treatment as factor and value at randomization as covariate. Two-sided nominal *P*-values are presented.

CI, confidence interval; LS, least-squares; VEGF-A, vascular endothelial growth factor A.